In the latest Endpoints 100 survey, 58% of biotech executives rated the flow of venture capital investments as "poor," the highest percentage in the survey's nine-year history.

In the latest Endpoints 100 survey, zero respondents rated the flow of venture capital investments as "excellent."

FDA Commissioner Marty Makary has stated a goal to accelerate the approval of rare disease drugs and reduce regulatory requirements.